MapLight Therapeutics, Inc. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how MapLight Therapeutics performed this year. My goal is to explain their latest filing in plain language so you can decide if this company fits your investment goals.

1. What does this company do?

MapLight is a clinical-stage biopharmaceutical company. They research and develop medicines for brain-related conditions like schizophrenia, Alzheimer’s-related psychosis, and Autism Spectrum Disorder.

They have no products on the market yet, so they earn no money from sales. Instead, they use their "MapLight Circuit-Based Drug Discovery" platform. This system uses AI and advanced mapping to find misfiring brain circuits and design targeted treatments to fix them.

2. The "Pipeline": Their Path to Profit

Since they have no products to sell, their value depends entirely on their "pipeline" of drugs in development:

• ML-007C-MA (Schizophrenia & Alzheimer’s): This is their lead treatment. They expect results for the schizophrenia trial in Q3 2026 and for the Alzheimer’s-related psychosis trial in the second half of 2027.
• ML-004 (Autism): This drug targets social communication challenges in autism. They have finished enrolling patients for their "IRIS" trial and expect results in Q3 2026.

3. Financial Health: Spending to Build the Future

It is important to be clear: MapLight is currently losing money. Because they have no products to sell, they have zero revenue.

• The Losses: In 2025, the company lost $161.2 million, more than double their $77.6 million loss in 2024. This jump happened because they spent $68.4 million more on research and clinical trials.
• The Deficit: Since they started, they have accumulated a total loss of $360.5 million.
• Cash Position: As of December 31, 2025, the company held $112.8 million in cash.
• What this means: They are spending heavily on research and the costs of being a public company. Management expects their current cash to last only into the first half of 2027. They will likely need to raise more money by selling more shares, which would reduce your ownership percentage, before their 2026 trial results are even fully analyzed.

4. The "Moat" and Regulatory Risks

MapLight holds 86 patents, with protection for their lead drug potentially lasting until 2046. However, the regulatory environment is challenging:

• Price Controls: New government policies may cap drug prices, which could lower profit margins for their brain-related drugs.
• Legal Hurdles: Recent Supreme Court rulings limit the power of federal agencies like the FDA, creating an environment where approval standards could shift.
• Data & Compliance: They must follow strict privacy laws. Any breach of patient data could invalidate their trial results or lead to significant fines.

5. The Bottom Line

MapLight is a high-risk, high-reward investment. You aren't buying them for current profits—because there aren't any. You are buying them because you believe their science and patents will lead to successful medicines. With losses doubling and cash running low by 2027, the company must deliver strong results in their 2026 trials to survive and grow.

Investor Checklist:

• Timeline: Are you comfortable waiting until at least Q3 2026 for the first major trial results?
• Dilution Risk: Are you prepared for the possibility that the company may issue more shares to raise cash before they have a product to sell?
• Risk Tolerance: Does your portfolio have room for a company that is currently burning cash with no guarantee of FDA approval?